Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16045492 | 0.86 | APP (0.41) | APPCA1CA2LMNAEPHX2 | |
| SCHEMBL5014277 | 0.84 | APP (0.39) | APPCA1CA2LMNAEPHX2 | |
| SCHEMBL14114301 | 0.82 | ALDH1A1 (0.39) | APPKDM4EALDH1A1LMNATSHR | |
| SCHEMBL13804841 | 0.82 | ALDH1A1 (0.39) | APPKDM4EALDH1A1LMNATSHR | |
| SCHEMBL6599060 | 0.82 | APP (0.41) | APPKDM4EALDH1A1LMNATSHR | |
| SCHEMBL37545 | 0.82 | APP (0.48) | APPCA1CA2KDM4EUSP2 | |
| SCHEMBL4513199 | 0.81 | APP (0.37) | APPLMNA | |
| SCHEMBL13092692 | 0.80 | APP (0.39) | APPCA1CA2USP2TSHR | |
| SCHEMBL8740085 | 0.80 | APP (0.39) | APPCA1CA2KDM4EALDH1A1 | |
| SCHEMBL11788121 | 0.80 | TSHR (0.48) | APPCA1CA2ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2525798-B1 | ANAESTHETIC FORMULATION | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2017-08-09 | — | — | EP | claimed |
| US-8975245-B2 | Anaesthetic formulation | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2015-03-10 | — | — | US | claimed |
| US-8697678-B2 | Anaesthetic formulation | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2014-04-15 | — | — | US | claimed |
| US-20140066417-A1 | ANAESTHETIC FORMULATION | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2014-03-06 | — | — | US | claimed |
| US-20120316146-A1 | ANAESTHETIC FORMULATION | MONASH UNIVERSITY (AU) | 2012-12-13 | — | — | US | claimed |
| EP-4083075-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CyDex Pharmaceuticals, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3702374-B1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CYDEX PHARMACEUTICALS INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11208500-B2 | Manufacturing process for cyclodextrin derivatives | CYDEX PHARMACEUTICALS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3702374-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CyDex Pharmaceuticals, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200157252-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-05-21 | — | — | US | disclosed |
| US-10633462-B2 | Manufacturing process for cyclodextrin derivatives | CYDEX PHARMACEUTICALS, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180051098-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-02-22 | — | — | US | disclosed |
| EP-2916846-A1 | NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION | Goodchild Investments Pty Ltd. (AU) | 2015-09-16 | — | — | EP | disclosed |
| US-8975245-B2 | Anaesthetic formulation | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2015-03-10 | — | — | US | disclosed |
| EP-2814849-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | Cydex Pharmaceuticals, Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2014071449-A1 | NEUROACTIVE STEROIDS AND THEIR USE TO FACILITATE NEUROPROTECTION | GOODCHILD INVESTMENTS PTY LTD (AU) | 2014-05-15 | — | — | WO | disclosed |
| US-8697678-B2 | Anaesthetic formulation | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2014-04-15 | — | — | US | disclosed |
| US-20140066417-A1 | ANAESTHETIC FORMULATION | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2014-03-06 | — | — | US | disclosed |
| WO-2013123254-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CYDEX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-20120316146-A1 | ANAESTHETIC FORMULATION | MONASH UNIVERSITY (AU) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633462-B2 | Manufacturing process for cyclodextrin derivatives | DCXR, AGL, OSTC | APP 152/4885CA1 3313/4885CA2 3978/4885 |
| US-20120316146-A1 | ANAESTHETIC FORMULATION | OPRL1, CNR1, CNR2 | APP 736/4885CA1 227/4885CA2 554/4885 |
| US-20140066417-A1 | ANAESTHETIC FORMULATION | OPRL1, CNR1, CNR2 | APP 736/4885CA1 227/4885CA2 554/4885 |
| US-20200157252-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | DCXR, AGL, OSTC | APP 152/4885CA1 3313/4885CA2 3978/4885 |
| US-11208500-B2 | Manufacturing process for cyclodextrin derivatives | DCXR, AGL, OSTC | APP 152/4885CA1 3313/4885CA2 3978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.